Adial Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.77 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.77M shares, a 295.06% increase year-over-year.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 448.00K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 30.00K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 35.00K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 19.12K shares, a 19.66% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 23.80K shares, a 40.20% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 39.80K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 1.77M shares 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | 19.12K shares 10-K · filed 2026-03-05 | ||||
| 2025-06-30 | 448.00K shares 10-Q · filed 2025-11-13 | 478.00K shares derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2025-03-31 | 30.00K shares 10-Q · filed 2025-11-13 | ||||
| 2024-12-31 | 595.00K shares 10-K · filed 2025-03-04 | 23.80K shares 10-K · filed 2026-03-05 | |||
| 2023-12-31 | 39.80K shares 10-K · filed 2025-03-04 | ||||
| 2022-06-30 | 35.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 596.67K shares 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 561.67K shares 10-Q · filed 2022-05-16 | ||||
| 2019-09-30 | 1.75M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 1.75M shares derived: sum of 2 quarters · filed 2019-11-14 | 2.26M shares 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | 508.10K shares 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | 508.10K shares 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |